Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091096 | 1.00 | GSK3B (0.34) | GSK3BATRMTORPRKCAPRKCD | |
| SCHEMBL4094405 | 0.83 | GPR119 (0.42) | — | |
| SCHEMBL4099561 | 0.83 | GPR119 (0.42) | — | |
| SCHEMBL4094646 | 0.81 | MAP3K12 (0.37) | GSK3BATRPRKCAPRKCDPRKD1 | |
| SCHEMBL13708558 | 0.81 | MAPK14 (0.41) | — | |
| SCHEMBL4094592 | 0.81 | MAPK14 (0.41) | — | |
| SCHEMBL4094586 | 0.81 | MAPK14 (0.41) | — | |
| SCHEMBL4098944 | 0.81 | MAPK14 (0.41) | — | |
| SCHEMBL4089193 | 0.77 | ATR (0.34) | GSK3BATRMTOR | |
| SCHEMBL4089157 | 0.77 | ATR (0.34) | GSK3BATRMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582631-B2 | Paget's disease; muscular disorders; cardiovascular disorders; antiinflamamtory agents; antidiabetic agents; autoimmune disease; leukemia | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-06-11 | — | — | US | disclosed |
| EP-1727821-A1 | SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Amgen Inc. (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-08-18 | — | — | US | disclosed |
| WO-2005070934-A1 | SUBSTITUTED DIAZABICYCLOHEPTANES AND THEIR USE AS PROTEIN KINASE INHIBITORS | AMGEN INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149468-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | GSK3B 64/4885ATR 924/4885MTOR 252/4885 |
| US-20050182072-A1 | Substituted heterocyclic compounds and methods of use | HLA-DRB1, PRKDC, NFATC1 | GSK3B 86/4885ATR 1082/4885MTOR 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.